Robeco Institutional Asset Management B.V. Trims Stake in Insulet Co. (NASDAQ:PODD)

Robeco Institutional Asset Management B.V. lessened its position in Insulet Co. (NASDAQ:PODD) by 1.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 23,677 shares of the medical instruments supplier’s stock after selling 372 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Insulet were worth $6,181,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in PODD. Integrated Wealth Concepts LLC lifted its position in Insulet by 1.7% during the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock valued at $596,000 after buying an additional 42 shares during the period. Nisa Investment Advisors LLC lifted its position in Insulet by 1.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after acquiring an additional 43 shares during the period. Glenmede Trust Co. NA boosted its stake in Insulet by 2.3% during the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after acquiring an additional 47 shares in the last quarter. Graypoint LLC grew its holdings in Insulet by 5.3% in the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after purchasing an additional 47 shares during the period. Finally, Wedmont Private Capital increased its stake in shares of Insulet by 3.5% during the third quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock valued at $326,000 after purchasing an additional 48 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages have recently commented on PODD. TD Cowen boosted their price target on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. Raymond James upped their price target on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Sanford C. Bernstein assumed coverage on shares of Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target for the company. BTIG Research upped their price objective on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Citigroup lifted their target price on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $272.81.

Insulet Stock Performance

PODD opened at $278.38 on Friday. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $286.39. The company has a market cap of $19.53 billion, a price-to-earnings ratio of 47.67, a PEG ratio of 3.48 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company’s 50 day moving average is $268.69 and its 200 day moving average is $238.21.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The firm had revenue of $543.90 million during the quarter, compared to the consensus estimate of $518.50 million. During the same quarter in the previous year, the firm posted $0.71 EPS. On average, equities research analysts predict that Insulet Co. will post 3.22 EPS for the current year.

Insiders Place Their Bets

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.